CY1110445T1 - Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια - Google Patents
Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενειαInfo
- Publication number
- CY1110445T1 CY1110445T1 CY20081101477T CY081101477T CY1110445T1 CY 1110445 T1 CY1110445 T1 CY 1110445T1 CY 20081101477 T CY20081101477 T CY 20081101477T CY 081101477 T CY081101477 T CY 081101477T CY 1110445 T1 CY1110445 T1 CY 1110445T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diabetic
- disease
- ischemical
- gender treatment
- gender
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Είναι δυνατόν να ενισχυθεί η αγγειογένεση σε μια ισχαιμική θέση που έχει μειωθεί λόγω διαβήτη και να προκληθεί ίαση της ισχαιμικής ασθένειας με χορήγηση γονιδίου HGF (ηπατοκυτταρικού αυξητικού παράγοντα) στην διαβητική ισχαιμική θέση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30998499 | 1999-10-29 | ||
EP00971697A EP1142590B8 (en) | 1999-10-29 | 2000-10-26 | Gene therapy for diabetic ischemic disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110445T1 true CY1110445T1 (el) | 2015-04-29 |
Family
ID=17999746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101477T CY1110445T1 (el) | 1999-10-29 | 2008-12-22 | Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια |
Country Status (15)
Country | Link |
---|---|
US (3) | US20080268030A1 (el) |
EP (1) | EP1142590B8 (el) |
JP (1) | JP3877148B2 (el) |
KR (1) | KR20010108053A (el) |
CN (1) | CN1182874C (el) |
AT (1) | ATE409494T1 (el) |
AU (1) | AU778826B2 (el) |
CA (1) | CA2356701C (el) |
CY (1) | CY1110445T1 (el) |
DE (1) | DE60040383D1 (el) |
DK (1) | DK1142590T3 (el) |
ES (1) | ES2313907T3 (el) |
HK (1) | HK1041211A1 (el) |
PT (1) | PT1142590E (el) |
WO (1) | WO2001032220A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE395087T1 (de) | 1999-10-08 | 2008-05-15 | Anges Mg Inc | Hgf zur gentherapie der karidomyopathie |
CA2446946A1 (en) | 2001-05-09 | 2002-11-14 | Anges Mg, Inc. | Gene transfer of angiogenic factor for skin disease |
JP4441263B2 (ja) * | 2001-11-28 | 2010-03-31 | アンジェスMg株式会社 | 神経変性疾患遺伝子治療剤 |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
US20080213348A1 (en) * | 2002-06-06 | 2008-09-04 | Anges Mg, Inc. | Agents for gene therapy of cerebrovascular disorders |
DE60332748D1 (de) * | 2002-10-02 | 2010-07-08 | Anges Mg Inc | Arzneimittel gegen hörfunktionsstörungen |
JP4775940B2 (ja) * | 2004-06-29 | 2011-09-21 | アンジェスMg株式会社 | アロディニアの治療、改善、予防剤 |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
ES2556711T3 (es) * | 2008-04-09 | 2016-01-19 | Viromed Co., Ltd. | Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico |
EP2840957B1 (en) * | 2012-04-27 | 2024-01-03 | Stryker European Operations Limited | Optical coherent imaging medical device and method |
ES2773305T3 (es) | 2013-10-22 | 2020-07-10 | Helixmith Co Ltd | Composición para la prevención o tratamiento de la esclerosis lateral amiotrófica que utiliza dos o más isoformas del factor de crecimiento de hepatocitos |
RU2691654C1 (ru) * | 2018-06-05 | 2019-06-17 | Юрий Валентинович Червяков | Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии бедренной и подколенной артерий |
JP7212230B2 (ja) | 2018-07-19 | 2023-01-25 | ヘリックスミス カンパニー, リミテッド | ネイキッドdna遺伝子療法のための凍結乾燥した薬剤学的組成物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576177A (en) * | 1983-02-18 | 1986-03-18 | Webster Wilton W Jr | Catheter for removing arteriosclerotic plaque |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US5817022A (en) * | 1995-03-28 | 1998-10-06 | Sonometrics Corporation | System for displaying a 2-D ultrasound image within a 3-D viewing environment |
US5756122A (en) * | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
KR100725199B1 (ko) * | 1995-08-29 | 2007-08-16 | 안제스에무지 가부시키가이샤 | 에이치지에프유전자를함유하는약제 |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
US6893664B1 (en) * | 1996-06-17 | 2005-05-17 | Powderject Research Limited | Particle delivery techniques |
DK0922102T3 (da) * | 1996-07-03 | 2010-08-16 | Genentech Inc | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US6024703A (en) * | 1997-05-07 | 2000-02-15 | Eclipse Surgical Technologies, Inc. | Ultrasound device for axial ranging |
GB9709453D0 (en) * | 1997-05-10 | 1997-07-02 | Imp Cancer Res Tech | Polypedtides and their use in therapy |
WO1999036103A1 (en) * | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
CA2261255A1 (en) * | 1998-02-13 | 1999-08-13 | Ethicon, Inc. | Assessment of ischemic wound healing therapeutics |
US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
DE60021360T2 (de) * | 1999-04-15 | 2006-05-24 | Caritas St. Elizabeth's Medical Center of Boston, Inc., Boston | Vegf angiogenische wachstumsfaktoren zur behandlung von peripherer neuropathie |
US7125856B1 (en) * | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
US6440945B1 (en) * | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
ATE395087T1 (de) * | 1999-10-08 | 2008-05-15 | Anges Mg Inc | Hgf zur gentherapie der karidomyopathie |
KR100798566B1 (ko) * | 2000-06-27 | 2008-01-28 | 안제스에무지 가부시키가이샤 | 혈관 신생요법용 의약조성물 |
CA2446946A1 (en) * | 2001-05-09 | 2002-11-14 | Anges Mg, Inc. | Gene transfer of angiogenic factor for skin disease |
US20080213348A1 (en) * | 2002-06-06 | 2008-09-04 | Anges Mg, Inc. | Agents for gene therapy of cerebrovascular disorders |
WO2003103721A1 (ja) * | 2002-06-06 | 2003-12-18 | アンジェス エムジー株式会社 | 脳血管障害遺伝子治療剤 |
CN1717254A (zh) * | 2002-12-02 | 2006-01-04 | 安增子摩祺株式会社 | 用于治疗或预防血管生成-依赖性症状的组合物 |
-
2000
- 2000-10-26 PT PT00971697T patent/PT1142590E/pt unknown
- 2000-10-26 JP JP2001534424A patent/JP3877148B2/ja not_active Expired - Lifetime
- 2000-10-26 AU AU10523/01A patent/AU778826B2/en not_active Expired
- 2000-10-26 EP EP00971697A patent/EP1142590B8/en not_active Expired - Lifetime
- 2000-10-26 ES ES00971697T patent/ES2313907T3/es not_active Expired - Lifetime
- 2000-10-26 DK DK00971697T patent/DK1142590T3/da active
- 2000-10-26 AT AT00971697T patent/ATE409494T1/de active
- 2000-10-26 CA CA2356701A patent/CA2356701C/en not_active Expired - Lifetime
- 2000-10-26 WO PCT/JP2000/007502 patent/WO2001032220A1/ja active IP Right Grant
- 2000-10-26 DE DE60040383T patent/DE60040383D1/de not_active Expired - Lifetime
- 2000-10-26 CN CNB00803835XA patent/CN1182874C/zh not_active Expired - Lifetime
- 2000-10-26 KR KR1020017008242A patent/KR20010108053A/ko not_active Application Discontinuation
-
2002
- 2002-04-09 HK HK02102637.3A patent/HK1041211A1/zh unknown
-
2008
- 2008-04-04 US US12/080,715 patent/US20080268030A1/en not_active Abandoned
- 2008-12-22 CY CY20081101477T patent/CY1110445T1/el unknown
-
2010
- 2010-11-02 US US12/938,128 patent/US20110045061A1/en not_active Abandoned
-
2015
- 2015-09-28 US US14/867,866 patent/US20160250290A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160250290A1 (en) | 2016-09-01 |
HK1041211A1 (zh) | 2002-07-05 |
AU1052301A (en) | 2001-05-14 |
DE60040383D1 (de) | 2008-11-13 |
CN1339973A (zh) | 2002-03-13 |
KR20010108053A (ko) | 2001-12-07 |
AU778826B2 (en) | 2004-12-23 |
CA2356701C (en) | 2011-02-15 |
ES2313907T3 (es) | 2009-03-16 |
CN1182874C (zh) | 2005-01-05 |
EP1142590A1 (en) | 2001-10-10 |
WO2001032220A1 (fr) | 2001-05-10 |
PT1142590E (pt) | 2008-10-27 |
EP1142590B8 (en) | 2008-11-26 |
EP1142590B1 (en) | 2008-10-01 |
DK1142590T3 (da) | 2009-01-26 |
JP3877148B2 (ja) | 2007-02-07 |
US20080268030A1 (en) | 2008-10-30 |
EP1142590A4 (en) | 2005-01-26 |
US20110045061A1 (en) | 2011-02-24 |
CA2356701A1 (en) | 2001-05-10 |
ATE409494T1 (de) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110445T1 (el) | Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια | |
CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
DE60138709D1 (de) | Analoge der barbitursäure als therapeutische wirkstoffe | |
DK1162982T3 (da) | Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning | |
EA200000747A1 (ru) | СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА | |
EA199900861A1 (ru) | Усеченные белки, родственные фактору роста эндотелия сосудов | |
DE60040293D1 (de) | Verwendung von nikotin in der angiogenese und der vaskulogenese | |
BR0012450A (pt) | Benzimidazóis substituìdos | |
ATE442851T1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
ATE482227T1 (de) | Modulatoren pharmakologischer mittel | |
DK1151009T3 (da) | Antimikrobielt/endotoksin-neutraliserende polypeptid | |
DK0616536T3 (da) | Anvendelse af decorin eller biglycan til fremstilling af et lægemiddel til behandling af diabetesbetingede tilstande | |
DK0988059T3 (da) | Humane quinonreduktase-2-konjugater til ADEPT og GDEPT | |
DE60334147D1 (de) | Plazentäre alkalische phosphatase zur diabeteskontrolle | |
DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE444073T1 (de) | Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten | |
ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
IT1317930B1 (it) | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione | |
DE602004025328D1 (de) | Hypoxie-induzierbares vegf plasmid für ischämische erkrankung | |
HUP9800247A2 (hu) | Humán endoglin gén promóter és annak alkalmazása | |
TR200202110T2 (tr) | "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri" | |
Manning | The 2000 Bower Award for Business Leadership presented to William J. Rutter | |
ATE501278T1 (de) | Verfahren zur verwendung von il-21 |